Mihael H. Polymeropoulos, CEO, highlighted continued commercial momentum, stating "During the second quarter, we continued the expansion of the Fanapt sales force and also continued our broad ...

Management updated 2025 financial guidance, expecting "total revenues from Fanapt, HETLIOZ, and PONVORY of between $210 million and $230 million" and "year-end 2025 cash of between $260 million and ...

WASHINGTON, April 2, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Fanapt ® (iloperidone) tablets ...

Vanda Pharmaceuticals specializes in developing and commercializing therapies for neurological and rare disorders. Its main products include Fanapt®, an antipsychotic for schizophrenia and bipolar I ...

Fanapt is an atypical antipsychotic agent that has been used for the acute treatment of schizophrenia since its FDA approval in 2009. Vanda Pharmaceuticals' Hetlioz and Fanapt accounted for over 99% ...

Earnings call Vanda reported Q1 2025 revenue of $50M, up 5% YoY, driven by a 14% increase in Fanapt sales. Despite a net loss of $29.5M, the company reaffirmed 2025 revenue guidance of $210M–$250M and ...

On Wednesday, 12 November 2025, Vanda Pharmaceuticals (NASDAQ:VNDA) presented at the Stifel 2025 Healthcare Conference, outlining its strategic focus on expanding its product pipeline and enhancing ...